Polymer-Based Nanocapsules for Drug Delivery in Cardiovascular Diseases and Metabolic Syndrome
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 298
Special Issue Editors
Interests: pharmaceutical technology; nanotechnology; biotechnology; pharmacology
Interests: pharmaceutical technology; nanotechnology; biotechnology; pharmacology
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) remain a significant health challenge around the world. These conditions affect the heart, blood vessels, and the blood itself. Researchers have long sought innovative approaches to improve therapeutic outcomes and diagnostic capabilities for CVDs. Enter nanomedicine, a field dedicated to revolutionizing diagnostics and treatments. CVDs encompass coronary artery disease, heart failure, and hypertension. Their multifaceted nature demands targeted interventions. Nanoparticles can improve CVD drug delivery. Polymer-based nanoparticles have garnered attention due to their biocompatibility and versatility, offering a promising avenue for drug delivery and improving efficacy while minimizing side effects. Systemically injected nanotherapeutics aid in imaging and early disease detection. In this context, polymer-based nanoparticles hold immense promise for treating CVDs and health problems related to metabolic syndrome. Their biocompatibility and drug delivery enhancements position them as a critical area of research. As we delve deeper into this field, we may unlock novel solutions to combat CVDs and metabolic syndrome.
The proposed Special Issue aligns perfectly with our research interests, and we are excited about the opportunity to contribute to its success. We believe this topic has the potential to contribute to modern pharmacology by offering innovative nanotechnology-based solutions to treat metabolic syndrome and cardiovascular diseases. By bringing together a diverse team of experts, we can explore innovative research, review the latest advances, and provide valuable information for academics and practitioners alike. We would be committed to ensuring the highest scientific standards, rigorous peer review, and prompt publication of high-quality articles. We envision a collection of original research articles, reviews, and perspectives displaying the multifaceted aspects of nanophytopharmaceuticals, from formulation development to clinical trials.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: polymer-based nanoparticles for drug delivery in coronary artery disease, type 2 diabetes, dyslipidemia, hepatic steatosis, polycystic ovarian syndrome, chronic kidney disease, cancer, and myeloid acute leukemia.
We look forward to receiving your contributions.
Dr. Jesús Rafael Rodríguez Amado
Dr. Ariadna Lafourcade Prada
Dr. Arquimedes Gasparotto Junior
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanocapsules
- nanoparticles
- coronary diseases
- metabolic syndrome
- drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
